Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04396847 · ClinicalTrials.gov registry record · Phase 2
Laboratory Screening of Lorcaserin for Alcohol Use Disorder
A Phase 2 study, sponsored by The Mind Research Network.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT04396847 is a Phase 2 study that was terminated before completion, run by The Mind Research Network. The registered enrollment target is 5 participants.
The verdict
NCT04396847, a Phase 2 study, was terminated before completion, sponsored by The Mind Research Network.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
Heavy-drinking smokers, including those with alcohol use disorder (AUD), are at increased risk for numerous negative health outcomes relative to those who use alcohol or cigarettes only. Although heavy-drinking smokers are recognized as an important subgroup for clinical and public health interventions, there are presently no approved medications for the joint indication of alcohol reduction and smoking cessation. Based on evidence that the serotonin system plays a role in alcohol and nicotine consumption and relapse, this study aims to examine whether a serotonin medication alters alcohol and nicotine responses in smokers with AUD, informing its potential utility as a candidate therapy for this clinical subgroup.
Interventions
- DRUG Placebo oral tablet
- DRUG Lorcaserin Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-10-25 |
| Est. Completion | 2020-02-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04396847
The ClinicalTrials.gov registry entry for NCT04396847 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Mind Research Network, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral tablet is the first listed.
NCT04396847 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04396847 about?
NCT04396847 is a clinical study titled "Laboratory Screening of Lorcaserin for Alcohol Use Disorder". Heavy-drinking smokers, including those with alcohol use disorder (AUD), are at increased risk for numerous negative health outcomes relative to those who use alcohol or cigarettes only. Although heavy-drinking smokers are recognized as an important subgroup for clinical and public health interventi...
What is the current status of trial NCT04396847?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2019-10-25. Estimated completion is 2020-02-26.
What interventions are being tested in trial NCT04396847?
The interventions under investigation include: Placebo oral tablet (DRUG), Lorcaserin Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT04396847?
This trial is sponsored by The Mind Research Network, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.